HK1 and neoplasm: Metformin can block tumor progression induced by inflammasome activation in tumor-infiltrating immune cells, protect the intestinal barrier from the LPS-triggered damage by alleviating NF-κB phosphorylation, and directly inhibit the enzymatic activity of HK1 and HK2 [17, 18, 32].